Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer (NCT04922307) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
United States240 participantsStarted 2021-07-23
Plain-language summary
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT).
The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Renal masses ≥ cT2 (by any conventional imaging).
* N1 or M1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy).
* Male and female patients.
* 18 and older.
* Ejection fraction (EF) ≥ 45% by echocardiogram (ECHO).
* Adequate organ function as defined by:
* Hemoglobin ≥ 9 g/dL. Pre-operative allogenic blood transfusion is allowed.
* Platelets ≥ 100.000/μl.
* Albumin ≥ 2.5 g/dL.
* Aspartate Aminotransferase (AST) and alanine transaminase (ALT) ≤ 75U/L or total bilirubin ≤ 2.0 mg/dL.
* WBC within institutional normal limits.
* PT within institutional normal limits.
* INR \< 1.5 and PTT normal.
* Consent and compliance with all aspects of the study protocol.
Exclusion Criteria:
* Male and female younger than 18 years old.
* Non-surgical candidate
* Unstable angina.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.